|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM171210107 |
| 003 |
DE-627 |
| 005 |
20231223125202.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0571.xml
|
| 035 |
|
|
|a (DE-627)NLM171210107
|
| 035 |
|
|
|a (NLM)17602874
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Goldacker, S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Active vaccination in patients with common variable immunodeficiency (CVID)
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.10.2007
|
| 500 |
|
|
|a Date Revised 10.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro. Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21(low) B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II - especially in case of vaccines for which passive protection cannot be guaranteed
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Pneumococcal Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Polysaccharides
|2 NLM
|
| 700 |
1 |
|
|a Draeger, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Warnatz, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huzly, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Salzer, U
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Thiel, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Eibel, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schlesier, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peter, H H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 124(2007), 3 vom: 11. Sept., Seite 294-303
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:124
|g year:2007
|g number:3
|g day:11
|g month:09
|g pages:294-303
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 124
|j 2007
|e 3
|b 11
|c 09
|h 294-303
|